Novartis Patient Day on April 30 in Hamburg: Workshops and expert knowledge about …

Novartis Pharma GmbH

Nuremberg (OTS)

  • The upcoming Novartis MPN Patient Day on April 30, 2022 will provide affected people, their families, and interested parties the opportunity to get answers to urgent questions about MPN diseases.
  • Lectures and workshops impart expert knowledge about the diseases of myelofibrosis (MPN), polycythemia vera (PV) and CML (chronic myeloid leukemia).
  • Participation in this face-to-face event in April is only possible after registration www.mpn-patiententage.de And observing the applicable Corona regulations.

Focus on MPN Diseases: On April 30, 2022 from 10:00 am to 3:30 pm at the Reichshof near Hamburg Central Station, the current Novartis MPN Patient Day will be held as a face-to-face event under the auspices of Prof. Medical Doctor Ahmed Al-Majakly, Senior Physician at Asklepios St. George Clinic focusing on Hematology, Oncology and Stem Cell Transplantation. In the presented lectures and workshops, affected people, their relatives and interested parties receive sound scientific information in a language that can be understood by the patient about the diagnosis and treatment of myelofibrosis (MF), polycythemia vera (PV), and CML (chronic myeloid leukemia). Sick Day provides visitors with a great space to share experiences and the opportunity to speak to experts and ask urgent questions directly to specialists and speakers. You can register for the MPN in Hamburg at www.mpn-patiententage.de.

The term myeloproliferative neoplasm (MPN) covers a group of rare chronic diseases of the hematopoietic cells of the bone marrow. 1 What they all have in common is the production of certain blood cells in excess. This can subsequently lead to various complications such as blood clots, blockage of blood vessels or an increased tendency to bleed and significantly reduce the patient’s quality of life. 1 MPN diseases can burden those affected with many symptoms – these include extreme tiredness or fatigue (tiredness), dizziness, itching and circulatory disturbances in the hands and feet. With timely diagnosis and appropriate treatment individually tailored to the patient, the success of treatment can be positively affected and the patient’s quality of life can be restored.

The detailed program and updated information about the event can be accessed at www.mpn-patiententage.de. There is of course a safety concept for this face-to-face event that complies with the current coronavirus hygiene requirements. The number of site participants is limited, subject to registrations in the order in which they were received. The next Patient Day will take place on 25 June 2022 in Saarbrücken.

the reviewer

1. The Leukemia Competence Network. Available at www.kompetenznetz-leukaemie.de/content/patienten/leukaemien/mpn/ (last accessed: 08.04.2022.)

About Novartis

Novartis is reimagining medicine to help people live longer and better lives. As a leading global pharmaceutical company, we use scientific innovation and digital technologies to develop advanced treatments in areas with significant unmet medical needs. We are regularly among those companies that invest the most in research and development all over the world. Novartis products reach nearly 800 million people globally, and we’re looking for new ways to expand access to our latest treatments. About 108,000 people from more than 140 countries work at Novartis around the world. In Germany, Novartis employs about 7,000 people in ten locations. More information at https://www.novartis.de/ and https://www.novartis.com/

Media contact:

Catherine Rover
Novartis Pharma GmbH
Communication and Sharing Hematology
M: +49 151 11809406
katrin.rueffer@novartis.com

Novartis Pharma GmbH
Pharmaceutical communications and oncology
Ronstrass 25
90429 Nuremberg
www.novartis.com

Original content from: Novartis Pharma GmbH, transmitted by news aktuell

Leave a Comment